Skip to main content
Top
Published in: Clinical Rheumatology 9/2008

01-09-2008 | Brief Report

Decreased bone mineral density in adult familial Mediterranean fever patients: a pilot study

Authors: Elif Suyani, Mehmet Akif Ozturk, Serpil Muge Deger, Mehmet D. Demirag, Berna Goker, Seminur Haznedaroglu

Published in: Clinical Rheumatology | Issue 9/2008

Login to get access

Abstract

We investigated the association between familial Mediterranean fever (FMF) and osteoporosis (OP) in adult patients. Thirty-five attack-free FMF patients (28 females, 7 males; mean age 36.9 ± 5.7 years) were individually matched to control subjects on the basis of age (within 2 years) and sex. All patients were taking regular colchicine. Subjects having any condition that can cause decreased bone mineral density (BMD) were excluded from the study. BMD was measured at the spine and femur by dual X-ray absorptiometry (DXA). Data was given as the median (IQR). T scores of the spine were −0.700 (−1.097 to −0.262) and −0.450 (−0.830 to 0.112) in FMF patients and healthy controls, respectively (p > 0.05). T scores of the femur neck were −0.900 (−1.480 to −0.570) and −0.430 (−1.472 to 0.247) in FMF patients and healthy controls, respectively (p > 0.05). Total femur T scores were significantly lower in FMF patients than healthy controls (−0.780 [−1.222 to −0.085] vs. −0.100 [−0.765 to 0.537], respectively, p = 0.021). Total femur T scores were significantly decreased in adult patients with FMF. Ongoing subclinical inflammation may be associated with decreased bone mineral content in those patients.
Literature
1.
go back to reference Ozen S (2003) Familial Mediterranean fever: revisiting an ancient disease. Eur J Pediatr 162:449–454PubMedCrossRef Ozen S (2003) Familial Mediterranean fever: revisiting an ancient disease. Eur J Pediatr 162:449–454PubMedCrossRef
2.
go back to reference Orbach H, Ben-Chetrit E (2001) Familial Mediterranean fever A review and update. Minerva Med 92:421–430PubMed Orbach H, Ben-Chetrit E (2001) Familial Mediterranean fever A review and update. Minerva Med 92:421–430PubMed
4.
go back to reference Korkmaz C, Ozdogan H, Kasapcopur O et al (2002) Acute phase response in familial Mediterranean fever. Ann Rheum Dis 61:79–81PubMedCrossRef Korkmaz C, Ozdogan H, Kasapcopur O et al (2002) Acute phase response in familial Mediterranean fever. Ann Rheum Dis 61:79–81PubMedCrossRef
5.
go back to reference Köklü S, Öztürk MA, Balcı M et al (2005) Interferon-gamma levels in familial Mediterranean fever. Jt Bone Spine 72:38–40CrossRef Köklü S, Öztürk MA, Balcı M et al (2005) Interferon-gamma levels in familial Mediterranean fever. Jt Bone Spine 72:38–40CrossRef
6.
go back to reference Baykal Y, Saglam K, Yilmaz MI et al (2003) Serum sIL-2r, IL-6, IL-10 and TNF-a level in familial Mediterranean fever patients. Clin Rheumatol 22:99–101PubMedCrossRef Baykal Y, Saglam K, Yilmaz MI et al (2003) Serum sIL-2r, IL-6, IL-10 and TNF-a level in familial Mediterranean fever patients. Clin Rheumatol 22:99–101PubMedCrossRef
7.
go back to reference Bagci S, Toy B, Tuzun A et al (2004) Continuity of cytokine activation in patients with familial Mediterranean fever. Clin Rheumatol 23:333–337PubMedCrossRef Bagci S, Toy B, Tuzun A et al (2004) Continuity of cytokine activation in patients with familial Mediterranean fever. Clin Rheumatol 23:333–337PubMedCrossRef
8.
go back to reference Haznedaroglu S, Oztürk MA, Sancak B et al (2005) Serum interleukin 17 and interleukin 18 levels in familial Mediterranean fever. Clin Exp Rheumatol 23:77–80 Haznedaroglu S, Oztürk MA, Sancak B et al (2005) Serum interleukin 17 and interleukin 18 levels in familial Mediterranean fever. Clin Exp Rheumatol 23:77–80
9.
go back to reference Tunca M, Kirkali G, Soytürk M et al (1999) Acute phase response and evolution of familial Mediterranean fever. Lancet 353:1415PubMedCrossRef Tunca M, Kirkali G, Soytürk M et al (1999) Acute phase response and evolution of familial Mediterranean fever. Lancet 353:1415PubMedCrossRef
10.
go back to reference Ginaldi L, Di Benedetto MC, De Martinis M (2005) Osteoporosis, inflammation and ageing. Immun Ageing 2:14PubMedCrossRef Ginaldi L, Di Benedetto MC, De Martinis M (2005) Osteoporosis, inflammation and ageing. Immun Ageing 2:14PubMedCrossRef
11.
go back to reference Kearns AE, Khosla S, Kostenuik P (2008) Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 29:155–192PubMedCrossRef Kearns AE, Khosla S, Kostenuik P (2008) Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 29:155–192PubMedCrossRef
12.
go back to reference Duzova A, Ozaltin F, Ozon A et al (2004) Bone mineral density in children with familial Mediterranean fever. Clin Rheumatol 23:230–234PubMedCrossRef Duzova A, Ozaltin F, Ozon A et al (2004) Bone mineral density in children with familial Mediterranean fever. Clin Rheumatol 23:230–234PubMedCrossRef
14.
go back to reference Raisz LG (1999) Physiology and pathophysiology of bone remodeling. Clin Chem 45:1353–1358PubMed Raisz LG (1999) Physiology and pathophysiology of bone remodeling. Clin Chem 45:1353–1358PubMed
15.
go back to reference Miller PD (2006) Guidelines for the diagnosis of osteoporosis: T-scores vs fractures. Rev Endocr Metab Disord 7:75–89PubMedCrossRef Miller PD (2006) Guidelines for the diagnosis of osteoporosis: T-scores vs fractures. Rev Endocr Metab Disord 7:75–89PubMedCrossRef
16.
go back to reference Clowes JA, Riggs BL, Khosla S (2005) The role of immune system in the pathophsiology of osteoporosis. Immunol Rev 208:207–227PubMedCrossRef Clowes JA, Riggs BL, Khosla S (2005) The role of immune system in the pathophsiology of osteoporosis. Immunol Rev 208:207–227PubMedCrossRef
17.
go back to reference McClung M (2007) Role of RANKL inhibition in osteoporosis. Arthritis Res Ther 9(Suppl 1):1–3CrossRef McClung M (2007) Role of RANKL inhibition in osteoporosis. Arthritis Res Ther 9(Suppl 1):1–3CrossRef
18.
go back to reference Tanaka S, Nakamura K, Takahasi N et al (2005) Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL–RANK signaling system. Immunol Rev 208:30–49PubMedCrossRef Tanaka S, Nakamura K, Takahasi N et al (2005) Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL–RANK signaling system. Immunol Rev 208:30–49PubMedCrossRef
19.
go back to reference Romas E, Gillespie T, Martin TJ (2002) Involvement of receptor activator of NFKB ligand and tumor necrosis factor-a in bone destruction in rheumatoid arthritis. Bone 30:340–346PubMedCrossRef Romas E, Gillespie T, Martin TJ (2002) Involvement of receptor activator of NFKB ligand and tumor necrosis factor-a in bone destruction in rheumatoid arthritis. Bone 30:340–346PubMedCrossRef
20.
go back to reference Tang BM, Eslick GD, Nowson C et al (2007) Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 370:657–666PubMedCrossRef Tang BM, Eslick GD, Nowson C et al (2007) Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 370:657–666PubMedCrossRef
21.
go back to reference Kessenich CR (2007) Nonpharmacological prevention of osteoporotic fractures. Clin Interv Aging 2:263–266PubMed Kessenich CR (2007) Nonpharmacological prevention of osteoporotic fractures. Clin Interv Aging 2:263–266PubMed
22.
go back to reference Deprez X, Fardellone P (2003) Nonpharmacological prevention of osteoporotic fractures. Jt Bone Spine 70:448–457CrossRef Deprez X, Fardellone P (2003) Nonpharmacological prevention of osteoporotic fractures. Jt Bone Spine 70:448–457CrossRef
Metadata
Title
Decreased bone mineral density in adult familial Mediterranean fever patients: a pilot study
Authors
Elif Suyani
Mehmet Akif Ozturk
Serpil Muge Deger
Mehmet D. Demirag
Berna Goker
Seminur Haznedaroglu
Publication date
01-09-2008
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 9/2008
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-008-0930-0

Other articles of this Issue 9/2008

Clinical Rheumatology 9/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.